www.tajpharma.com

APIDRYL®

20/80/160 MG

DOCETAXEL INJECTION, USP

APIDRYL®

20/80/160 MG

DOCETAXEL INJECTION, USP

A CHEMOTHERAPY DRUG USUALLY GIVEN TO TREAT BREAST CANCER,
PROSTATE CANCER AND NON-SMALL CELL LUNG CANCER.

CLASS - ANTINEOPLASTIC

INDICATIONS AND USAGE
Apidryl ® DOCETAXEL INJECTION, USP is a microtubule inhibitor indicated for:
Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC
Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC
Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer.
DOSAGE AND ADMINISTRATION
Administer in a facility equipped to manage possible complications (e.g., anaphylaxis). Administer intravenously over 1 hr every 3 weeks.
PVC equipment is not recommended..
BC locally advanced or metastatic: 60 mg/m2 to 100 mg/m2 single agent
BC adjuvant: 75 mg/m2 administered 1 hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles (2.1)
NSCLC: after platinum therapy failure: 75 mg/m2 single agent
NSCLC: chemotherapy-naive: 75 mg/m2 followed by cisplatin 75 mg/m2
HRPC: 75 mg/m2 with 5 mg prednisone twice a day continuously
For all patients:
Premedicate with oral corticosteroids
Adjust dose as needed

DOSAGE FORMS AND STRENGTHS : Apidryl ® DOCETAXEL INJECTION, USP

20 mg/2 mL single use vial
80 mg/8 mL multi-use vial
160 mg/16 mL multi-use vial

A Taj Pharma"India Product